The Diagnostic Value of Captopril Challenge Test for Primary Aldosteronism

CHEN Shi-han; LUO Pan-yu; YU Ye-rong

doi:10.12182/20201260301

Volume 52 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Abstract

References

JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) > 2021 > 52(1): 134-141. > DOI: 10.12182/20201260301

CHEN Shi-han, LUO Pan-yu, YU Ye-rong. The Diagnostic Value of Captopril Challenge Test for Primary Aldosteronism[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(1): 134-141. DOI: 10.12182/20201260301

Citation:

PDF (594 KB)

The Diagnostic Value of Captopril Challenge Test for Primary Aldosteronism

Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Corresponding author:
YU Ye-rong, E-mail: yerongyu@scu.edu.cn
Received Date: October 14, 2019
Revised Date: July 28, 2020
Available Online: January 19, 2021
Published Date: January 19, 2021

Abstract

Abstract

Objective To investigate the diagnostic value of different captopril challenge test (CCT) diagnostic criteria for diagnosing primary aldosteronism (PA).
Methods We collected the clinical data of 184 patients with hypertension retrospectively in West China Hospital of Sichuan University. Receiver operating characteristic (ROC) curves were used to analyze the post-CCT efficacy of aldosterone renin activity ratio (ARR), plasma aldosterone concentration (PAC), plasma renin activity (PRA) and PAC suppression rate for PA diagnosis.
Results This study included 125 cases of primary aldehyde (PA group) and 59 cases of essential hypertension (EH group), and there were 38 normal renin primary hypertension (NREH group) and 21 low renin primary hypertension (LREH group) in EH group. The post-CCT PAC suppression rate (median (P₂₅,P₇₅)) of EH and PA group were 0.190 (0.083, 0.351) and 0.125 (0.024, 0.237), respectively. Compared with the NREH group, the basic and post-CCT PRA of LREH group were lower (P<0.001), and there were no significant differences compared with the PA group (P>0.05). We found significant overlap of post-CCT PRA and ARR between PA group and LREH group, while the overlap of post-CCT PAC between the two groups was small. In differential diagnosis of PA and EH, the areas under ROC curve of the post-CCT ARR, PAC, PRA and PAC suppression rate were 0.860 (95% confidence interval (CI): 0.800-0.907), 0.881 (95%CI: 0.825-0.924), 0.771 (95%CI: 0.703-0.831) and 0.632 (95%CI: 0.558-0.701), respectively. There was no significant difference between the first two indexes (Z=0.443, P=0.658), and both of them were higher than the latter two (P<0.05). The optimal post-CCT cut-off values for ARR and PAC in differential diagnosis of PA and EH were 19.24 ng·dL⁻¹ with a sensitivity of 78.4% and a specificity of 88.1%, and 32.47 (ng·dL⁻¹)/(ng·mL⁻¹·h⁻¹) with a sensitivity of 84.17% and a specificity of 72.41%.
Conclusion Both ARR and PAC have higher diagnostic value than the post-CCT PAC suppression rate, post-CCT PAC is especially suitable as a confirmatory testing criterion of PA.
- Primary aldosteronism,
- Essential hypertension,
- Captopril challenge test

FullText(HTML)

References (26)

References

[1]	MONTICONE S, BURRELLO J, TIZZANI D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol,2017,69(14): 1811–1820. DOI: 10.1016/j.jacc.2017.01.052
[2]	HUNG C S, SUNG S H, LIAO C W, et al. Aldosterone induces vascular damage. Hypertension,2019,74(3): 623–629. DOI: 10.1161/HYPERTENSIONAHA.118.12342
[3]	FRUSTACI A, LETIZIA C, VERARDO R, et al. Primary aldosteronism-associated cardiomyopathy: clinical-pathologic impact of aldosterone normalization. Int J Cardiol,2019,292: 141–147. DOI: 10.1016/j.ijcard.2019.06.055
[4]	FUNDER J W, CAREY R M, MANTERO F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocr Metab,2016,101(5): 1889–1916. DOI: 10.1210/jc.2015-4061
[5]	ENDOCRINOLOGY C S O. Primary aldosteronism: consensus for diagnosis and treatment. Chin J Endocrinol Metab,2016,32(3): 188–195.
[6]	DA H, C A, M Q, et al. Safety of medical adjustment and confirmatory testing in the diagnostic workup of primary aldosteronism. Eur J Endocrinol,2019,181(4): 421–428. DOI: 10.1530/EJE-19-0138
[7]	MENG X, LI Y, WANG X, et al. Evaluation of the saline infusion test and the captopril challenge test in Chinese patients with primary aldosteronism. J Clin Endocrinol Metab,2018,103(3): 853–860. DOI: 10.1210/jc.2017-01530
[8]	赵玲, 王琳, 宋烨琼, 等. 卡托普利抑制试验中原醛症最佳诊断指标的探讨. 解放军医学杂志,2018,43(9): 553–558. DOI: 10.11855/j.issn.0577-7402.2018.07.02
[9]	陈适, 曾正陪, 宋爱羚, 等. 卡托普利试验在原发性醛固酮增多症诊断中的应用. 中华内科杂志,2017,56(6): 402–408. DOI: 10.3760/cma.j.issn.0578-1426.2017.06.004
[10]	ZHU K Y, ZHANG Y, ZHANG W J, et al. The captopril challenge test for diagnosing primary aldosteronism in a Chinese population. BMC Endocr Disord,2019,19(1): 65–71. DOI: 10.1186/s12902-019-0390-3
[11]	SONG Y, YANG S, HE W, et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension,2018,71(1): 118–124. DOI: 10.1161/HYPERTENSIONAHA.117.10197
[12]	KIDOGUCHI S, SUGANO N, HAYASHI-ISHIKAWA N, et al. The characteristics of captopril challenge test-positive patients using various criteria. J Renin Angiotensin Aldosterone Syst, 2019, 20(3): 1470320319870891[2019-10-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709445.doi:10.1177/1470320319870891" target="_blank">10.1177/1470320319870891">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709445.doi:10.1177/1470320319870891.
[13]	李岩岩, 刘玉平, 李建薇. 卡托普利试验诊断原醛症的切点分析. 四川大学学报(医学版),2014,45(6): 1030–1032.
[14]	GOTO T, ABE K, TSUNODA K, et al. The changes in active and inactive renin induced by various maneuvers in hypertensive patients. Tohoku J Exp Med,1986,149(2): 169–181. DOI: 10.1620/tjem.149.169
[15]	SEALEY J E, GORDON R D, MANTERO F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrin Met,2005,16(3): 86–91. DOI: 10.1016/j.tem.2005.02.006
[16]	MULATERO P, VERHOVEZ A, MORELLO F, et al. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf),2007,67(3): 324–334. DOI: 10.1111/j.1365-2265.2007.02898.x
[17]	BAUDRAND R, GUARDA F J, FARDELLA C, et al. Continuum of renin-independent aldosteronism in normotension. Hypertension,2017,69(5): 950-956. DOI: 10.1161/HYPERTENSIONAHA.116.08952
[18]	RIOS M C, IZQUIERDO A, SOTELO M, et al. Aldosterone/renin ratio in the diagnosis of primary aldosteronism. Medicina (B Aires),2011,71(6): 525–530.
[19]	SCHWARTZ G L, TURNER S T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem,2005,51(2): 386–394. DOI: 10.1373/clinchem.2004.041780
[20]	YIN G S, ZHANG S L, YAN L, et al. Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups. Endocrine,2012,42(1): 182–189. DOI: 10.1007/s12020-012-9609-z
[21]	李芳, 谢小英, 赵铁耘. 醛固酮/肾素比值联合低肾素水平诊断原发性醛固酮增多症的准确性. 四川大学学报(医学版),2010,41(3): 501–504.
[22]	陈绍行, 杜月凌, 张瑾, 等. 在高血压患者中筛选原发性醛固酮增多症国人血浆醛固酮/肾素活性比值标准的探讨. 中华心血管病杂志,2006,34(10): 868–872. DOI: 10.3760/j:issn:0253-3758.2006.10.002
[23]	徐媛媛, 蒋怡然, 苏颠为, 等. 醛固酮_肾素比值在原发性醛固酮增多症筛查中的临床价值. 中华内分泌代谢杂志,2012,28(4): 301–305. DOI: 10.3760/cma.j.issn.1000-6699.2012.04.013
[24]	李元美, 王雯, 李千瑞, 等. 探索不同方法对原发性醛固酮增多症的筛查价值. 四川大学学报(医学版),2020,51(3): 278–286. DOI: 10.12182/20200360504
[25]	WESTERDAHL C, BERGENFELZ A, ISAKSSON A, et al. Captopril suppression: limitations for confirmation of primary aldosteronism. J Renin Angiotensin Aldosterone Syst,2011,12(3): 326–332. DOI: 10.1177/1470320310390405
[26]	JH K, KS P, AR H, et al. Diagnostic role of captopril challenge test in korean subjects with high aldosterone-to-renin ratios. Endocrinol Metab (Seoul),2016,31(2): 277–283. DOI: 10.3803/EnM.2016.31.2.277

Relative Articles

Supplements (0)

Cited By

Get Citation

PDF

XML

Article views (1599) PDF downloads (37)

The Diagnostic Value of Captopril Challenge Test for Primary Aldosteronism

Abstract

References

Catalog

Export File

Citation

Format

Content